PANTOPRAZOLE SODIUM DELAYED-RELEASE
Manufacturer: Lifestar Pharma LLC
Score: 141.0
Pantoprazole sodium delayed-release is a proton pump inhibitor (PPI) used for the short-term treatment of erosive esophagitis (EE) associated with gastroesophageal reflux disease (GERD), maintenance of healing of EE, and pathological hypersecretory conditions including Zollinger-Ellison syndrome. The recommended dosage is 40 mg once daily for up to 8 weeks for adults and children 5 years and older. Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole and in patients receiving rilpivirine-containing products. Common adverse reactions include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia.
Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole and in patients receiving rilpivirine-containing products.
No dose adjustment is needed for patients with mild to moderate hepatic impairment or renal impairment.
40 mg once daily for up to 8 weeks
20 mg once daily for up to 8 weeks for children 5-14 years old, 40 mg once daily for up to 8 weeks for children 15 years and older
40 mg once daily
Not established
40 mg twice daily
Not established